An Evaluation of the Suppression of CDKN2B Contributes to the Recovery of Chemosensitivity of Enzalutamide-resistant Prostate Cancer Cells

An Evaluation of the Suppression of CDKN2B Contributes to the Recovery of Chemosensitivity of Enzalutamide-resistant Prostate Cancer Cells

LIU Yafei, SUN Zhaonan, WANG Liang, QI Feng

PDF(6226 KB)

Welcome to Labeled Immunoassays and Clinical Medicine website! Share:

PDF(6226 KB)

Labeled Immunoassays and Clinical Medicine ›› 2023, Vol. 30 ›› Issue (5) : 833-839. DOI: 10.11748/bjmy.issn.1006-1703.2023.05.021

Original Article

An Evaluation of the Suppression of CDKN2B Contributes to the Recovery of Chemosensitivity of Enzalutamide-resistant Prostate Cancer Cells

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2023, 30(5): 833-839 https://doi.org/10.11748/bjmy.issn.1006-1703.2023.05.021

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}

{{article.copyrightLicense_en}}

PDF(6226 KB)

Accesses

Citation

Detail

Sections

Recommended

/

〈

〉